AOD-9604 in Étables — Fat Loss Peptide Research Guide
AOD-9604 research guide for Étables. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't stocked on pharmacy shelves in Étables or virtually any local market — this is a specialist compound distributed through a dedicated online market. This matters because AOD-9604 quality ranges widely across the market — from verified research-grade material to products with serious contamination — and the vendor determines everything about the product. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis containing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. The sections below cover what Étables researchers need to know about finding, evaluating, and storing AOD-9604 for scientific research use.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Étables studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Buying AOD-9604: Quality Markers to Look For
The most effective path to quality AOD-9604 is starting with community forums — peptide forums aggregate real purchasing experience that are more reliable than search results. The HPLC analytical chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be at or above 98%. Negative indicators in AOD-9604 vendor evaluation: prices more than 30-40% below standard market rates, unclear production details, no community presence, and COAs that lack endotoxin data. The powdered lyophilised form of AOD-9604 is always preferable to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations lose activity within weeks.
Order AOD-9604 — ships to Étables
COA-verified · International tracking · Research grade
AOD-9604 is available for research use only and is not approved for human consumption by the FDA or equivalent agencies worldwide — all information here is educational. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with bacteriostatic water. The primary quality-related safety risk in AOD-9604 research is bacterial endotoxin from low-quality material — a documented endotoxin result in your specific batch certificate is the key safeguard. PubMed and bioRxiv are the primary literature resources for AOD-9604 research; focus on peer-reviewed publications with documented compound quality over case reports or anecdotal evidence.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
